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In Brief
The maintenance of Foxp3 expression is
critical for correct TREG cell function.
Fleskens et al. demonstrate a molecular
mechanism in which TCR engagement
can stabilize Foxp3 protein expression
through TAK1-NLK-regulated
phosphorylation, thereby maintaining
TREG cell suppressive function.
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The Foxp3 transcription factor is a crucial determi-
nant of both regulatory T (TREG) cell development
and their functional maintenance. Appropriate mod-
ulation of tolerogenic immune responses therefore
requires the tight regulation of Foxp3 transcriptional
output, and this involves both transcriptional and
post-translational regulation. Here, we show that
during T cell activation, phosphorylation of Foxp3
in TREG cells can be regulated by a TGF-b activated
kinase 1 (TAK1)-Nemo-like kinase (NLK) signaling
pathway. NLK interacts and phosphorylates Foxp3
in TREG cells, resulting in the stabilization of protein
levels by preventing association with the STUB1
E3-ubiquitin protein ligase. Conditional TREG cell
NLK-knockout (NLKDTREG) results in decreased
TREG cell-mediated immunosuppression in vivo, and
NLK-deficient TREG cell animals developmore severe
experimental autoimmune encephalomyelitis. Our
data suggest a molecular mechanism, in which stim-
ulation of TCR-mediated signaling can induce a
TAK1-NLK pathway to sustain Foxp3 transcriptional
activity through the stabilization of protein levels,
thereby maintaining TREG cell suppressive function.
INTRODUCTION
Immunological tolerance and homeostasis are established by a
specific subset of T lymphocytes called regulatory T (TREG) cells,3600 Cell Reports 26, 3600–3612, March 26, 2019 ª 2019 The Autho
This is an open access article under the CC BY-NC-ND license (http://which are characterized by a highly specialized suppressive
phenotype (Fontenot et al., 2003; Khattri et al., 2003). The Fork-
head Box transcription factor Foxp3 is a crucial determinant of
TREG cell development and function, illustrated by the onset of a
fatal complex autoimmune disorder in humans andmice, caused
by loss-of-function mutations in the gene encoding Foxp3 (Ben-
nett et al., 2001; Khattri et al., 2003). Foxp3 expression levels
are tightly regulated, and the maintenance of Foxp3 expression
is crucial for sustained TREG cell suppressive function (Williams
and Rudensky, 2007). Foxp3+ TREG cells are frequently found in
large numbers at inflammatory loci in diseases, including type 1
diabetes, multiple sclerosis, and rheumatoid arthritis, but they
fail to control immune responses at the site of inflammation (Eh-
renstein et al., 2004; Lindley et al., 2005; Viglietta et al., 2004).
These findings illustrate that physiological cues encountered
within the TREGcellmicroenvironment canmodulate their function
through a variety of as yet unresolved molecular mechanisms.
It has been appreciated for some time that there is a require-
ment for TCR signaling for Foxp3 expression and that T cell
receptor (TCR) signaling precedes the induction of FOXP3 tran-
scription (Li and Rudensky, 2016). While it appears that a broad
range of high-affinity antigens probably drives TREG cell differen-
tiation, there is also evidence that thymic-derived TREG cell TCRs
continually sample (high-affinity) antigens (Moran et al., 2011).
TCR expression does not appear to be to be required for the
maintenance of resting TREG cells; however, continuous TCR
signaling is observed in these cells (Levine et al., 2014; Vahl
et al., 2014). Furthermore, TREG cell-specific deletion of the
TCR a chain has shown that TCR signaling is critical for the gen-
eration andmaintenance of activated and suppressive TREG cells
(Levine et al., 2014; Vahl et al., 2014). The identification of key
signaling pathways induced downstream of TCR engagementrs.
creativecommons.org/licenses/by-nc-nd/4.0/).
is required to fully understand the mechanism driving TREG cell
development and maintenance of immune tolerance. While
TCR signaling regulates a variety of transcriptional events that
aremediated by nuclear factor kB (NF-kB), nuclear factor of acti-
vated T cells (NFAT), and ForkheadBox subfamily O (FOXO) tran-
scription factors, what is much less well defined is whether TCR
stimulation may also result in the activation of intracellular
signaling pathways that directly impinge on Foxp3 function. It is
becoming increasingly evident that post-translational modula-
tors can fine-tune Foxp3 transcriptional activity, thereby modu-
lating TREG cell suppressive function. This can include interaction
with co-factors that can redirect Foxp3 transcriptional output un-
der distinct environmental conditions (Kwon et al., 2017; Rudra
et al., 2012) or through post-translational modifications (Lu
et al., 2017; van Loosdregt and Coffer, 2014). The modification
of Foxp3 protein by means of acetylation, for example, can
modulate several aspects of its transcriptional activity. Depend-
ing on the targeted lysine residue, acetylation of Foxp3 can
improve its ability to regulate gene transcription by enhancing
protein oligomerization, as well as binding to active chromatin
sites (Samanta et al., 2008; Song et al., 2012). Furthermore, tem-
poral control of Foxp3protein stability results froma tight balance
between lysine acetylation and poly-ubiquitination, allowing for
transient modulation of TREG cell function (van Loosdregt et al.,
2010). In response to inflammatory cytokines such as inter-
leukin-6 (IL-6), enhanced proteasomal degradation results from
increased poly-ubiquitination by STUB1, as well as decreased
ubiquitin-specific peptidase 7 (USP7)-mediated deubiquitination
of Foxp3 protein (Chen et al., 2013; van Loosdregt et al., 2013a).
In addition, cyclin-dependent kinase 2 (CDK2)-mediated phos-
phorylation of CDK motifs in the N terminus of Foxp3 was sug-
gested to impede protein stability, whereas tumor necrosis
factor a (TNF-a)-induced dephosphorylation of Foxp3 negatively
modulated TREG cell function in rheumatoid arthritis (Morawski
et al., 2013; Nie et al., 2013). Further understanding of themolec-
ular mechanisms and key players involved in the regulation of
Foxp3 function is required to elucidate the mechanisms that
can either impede or invigorate TREG function to establish a
balanced immune response.
Here, we describe a novel TCR-mediated signaling pathway
regulating Foxp3 phosphorylation through the activation of
Nemo-like kinase (NLK) in a transforming growth factor b
(TGF-b) activated kinase 1 (TAK1)-dependent manner. NLK-
mediated phosphorylation of Foxp3 results in the stabilization
of protein levels by preventing ubiquitin-mediated proteasomal
degradation. Conditional deletion of NLK in TREG cells results
in the loss of in vivo suppressive capacity and an age-dependent
increase in autoinflammation. The identification of such novel
intracellular modulators of Foxp3 that affect TREG cell homeosta-
sis and function provides potential therapeutic targets for con-
trolling immune tolerance and regulating these cells in a variety
of pathogenic conditions.
RESULTS
Phosphorylation of Foxp3 Is Regulated by TAK1
Almost 15% of the human Foxp3 protein is composed of amino
acids that could be subjected to phosphorylation (14% in mu-rine Foxp3), of which the majority is either serine (Ser) or threo-
nine (Thr) (40 and 19 residues, respectively) (Figure 1A). To
enable the detection of putatively phosphorylated residues in
the Foxp3 protein, we used Phos-tag Acrylamide, followed by
SDS-PAGE (Takeda et al., 2003). Human in vitro-induced TREG
(iTREG) cells were generated from naive CD4
+ T cells isolated
from umbilical cord blood (UCB), as previously described
(van Loosdregt et al., 2013a, 2013b), and subsequently treated
with increasing concentrations of the Ser/Thr phosphatase
inhibitor okadaic acid (OA). A decrease in the electrophoretic
mobility of Foxp3 protein, indicative of phosphorylation, was
already observed in untreated cells, but markedly increased
upon treatment with OA in a dose-dependent manner (Fig-
ure 1B). The appearance of multiple bands indicates that phos-
phorylation likely occurs on several residues. Furthermore, the
dependence on OA treatment indicates that this is a dynamic
process.
Protein phosphorylation is generally regulated upon the acti-
vation of signaling pathways by extracellular stimulation. Since
we initially detected Foxp3 phosphorylation in a system using
iTREG cells generated in the presence of IL-2, TGF-b, and anti-
CD3/anti-CD28 antibodies, we postulated that one or all of these
signals could be responsible for the observed modification. To
investigate this, we deprived differentiated iTREG cells from
IL-2, TGF-b, and CD3/CD28 stimulation for 24 h to downregulate
intracellular signal transduction pathways. Subsequently, we re-
activated signaling with each stimulus or in combination (Figures
1C–1E and S1A). Phos-tag analysis was used to detect phos-
phorylation, which could be observed only upon reactivation of
the TCR by incubation with CD3/CD28 antibodies. A combina-
tion of CD3/CD28 antibodies, IL-2, and TGF-b did not further
enhance Foxp3 phosphorylation, indicating that TCR activity
was sufficient for maximal Foxp3 phosphorylation. To evaluate
whether the phosphorylation observed upon OA treatment
indeed required prior TCR stimulation, we deprived iTREG cells
of differentiation stimuli for 24 h, and then induced TCR activity
in the presence or absence of OA (Figure 1C). In deprived iTREG
cells, the phosphorylation of Foxp3 was no longer observed
upon OA treatment, indicating that additional signals were
required. Upon the activation of TCR signaling, Foxp3 phosphor-
ylation was again induced, which was further enhanced when
cells were simultaneously treated with OA (Figure 1D). Next,
we used PMA (phorbol 12-myristate 13-acetate) and ionomycin
as alternative means to activate signaling events downstream of
the TCR (Figure 1E). Comparable to CD3/CD28 stimulation, PMA
and ionomycin could induce the phosphorylation of Foxp3, sup-
porting the notion that TCR activation is sufficient for Foxp3
phosphorylation.
Next, to investigate which protein kinases downstream of TCR
activation may be involved in the regulation of Foxp3 phosphor-
ylation, we took a candidate approach, pretreating iTREG cells
with specific inhibitors that targeted a variety of Ser/Thr kinases,
followed by OA incubation (Figures 1F, S1B, and S1C). Inhibitors
of the phosphatidylinositol 3-kinase-protein kinase B-mamma-
lian target of rapamycin (PI3K-PKB-mTOR) pathway, which is
believed to be an important determinant of TREG cell function
(Delgoffe et al., 2011; Haxhinasto et al., 2008; Sauer et al.,
2008), did not affect Foxp3 phosphorylation in this experimentalCell Reports 26, 3600–3612, March 26, 2019 3601
Figure 1. TAK1 Modulates Foxp3 Phosphorylation in Response to TCR Engagement
(A) Schematic overview of serine and threonine residues in human and mouse Foxp3 protein.
(B) Phos-tag analysis of iTREG cells treated with increasing concentrations of okadaic acid (OA; 0.1–0.2–0.5–1.0–2.0 mM).
(C–G) Phos-tag analysis of lysates from TREG cells deprived from IL-2, TGF-b, and TCR activation for 24 h.
(C) Deprived iTREG cells were restimulated with anti-CD3/CD28 coated beads and OA.
(D) Deprived iTREG cells were restimulated with IL-2, TGF-b, or anti-CD3/CD28 coated beads.
(E) Deprived iTREG cells were restimulated with anti-CD3/CD28 coated beads, PMA, and ionomycin to induce TCR downstream signaling.
(F) Phos-tag analysis of lysates from iTREG cells pre-treated for 2 h with kinase-specific inhibitors, before OA treatment (1 mM, 30 min).
(G) CD4+GFP+ TREG cells were sorted frommouse spleens, pre-incubated with TAK inhibitor (TAKi) (300 nM), and subsequently treated with OA, anti-CD3/CD28
coated beads, PMA, and ionomycin ex vivo for 30 min. Lysates were analyzed by Phos-tag-SDS-PAGE.setup. Neither did the inhibition of glycogen synthase kinase 3
(GSK-3), which we have recently demonstrated can modulate
TREG cell function through the regulation of bcatenin/T cell fac-
tor 1 (TCF1) activity (van Loosdregt et al., 2013b). A clear reduc-
tion in phosphorylation was, however, observed upon the inhibi-
tion of TAK1, whereas the inhibition of other mitogen-activated
protein kinase (MAPK) family members p38, Jun-N-terminal ki-
nase (JNK), and mitogen activated protein kinase kinase (MEK)
had no effect. Since T cell-specific deletion of Map3k7, the
gene encoding TAK1, results in the abrogation of TREG cell gen-
eration (Chang et al., 2015; Sato et al., 2006; Wan et al., 2006),
we hypothesized that the TAK1-mediated phosphorylation of
Foxp3 may play a role in the regulation of Foxp3 function.
To establish whether Foxp3 phosphorylation is also regulated
by TCR signaling in primary murine TREG cells, freshly isolated3602 Cell Reports 26, 3600–3612, March 26, 2019TREG cells from Foxp3-GFP mice were incubated with CD3/
CD28, PMA, and ionomycin, and phosphorylation was assessed
by Phos-tag analysis (Figure 1G). Again, stimulation with CD3/
CD28 antibodies induced the phosphorylation of Foxp3. TREG
intracellular signaling was apparently already occurring to
some extent in these cells, as indicated by the presence of
modest phosphorylation in untreated cells (Figure 1G, lane 1),
which accumulated upon OA treatment (Figure 1G, lane 3). How-
ever, phosphorylation was further enhanced upon the stimula-
tion of TCR signaling by either CD3/CD28 or ionomycin but not
PMA treatment (Figure 1G, lanes 2 and 4–7). Ionomycin triggers
intracellular Ca2+ release, which was previously demonstrated to
induce Ca2+/calmodulin-dependent kinase (CaMKII) to directly
phosphorylate TAK1, thereby inducing TAK1 signaling (Ishitani
et al., 2003; Wang et al., 2009). To assess the role of TAK1
Figure 2. NLK Interacts with and Directly Phosphorylates Foxp3
(A) Schematic representation of a conventional MAPK signal transduction pathway.
(B) Phos-tag analysis of Foxp3 co-expressed with MAPKs demonstrated to act downstream of TAK1.
(C) Phos-tag analysis of Foxp3 expressed in HEK293 cells in the presence or absence of ectopic NLK. Foxp3 was immunoprecipitated and immunoprecipitated
fractions were incubated with lPPAse for 30 min, as indicated.
(D) Co-immunoprecipitation of FLAG-NLK and HA-Foxp3. HEK293 cells transiently expressing FLAG-NLK and HA-Foxp3 as indicated were lysed, and lysates
were incubated with anti-FLAG M2 affinity gel.
(E) Representative confocal microscopy images of sorted CD4+GFP+ TREG cells from the spleen. Endogenous Foxp3 (green) and NLK (red) were visualized using
specific antibodies, and DAPI was used to visualize the nucleus.
(F) PLA analysis of Foxp3:NLK association immediately after cell sorting from spleen and MLN.
(G) In vitro kinase assay with ectopic HA-Foxp3 immunoprecipitated from HEK293 cells and purified active GST-NLK protein in the presence or absence of ATP.
Samples were analyzed by Phos-tag-SDS-PAGE.
(H) Schematic representation of NLK-dependent phosphorylated residues in Foxp3 identified by mass spectrometry. The asterisk indicates where phosphor-
ylated residues could not be unequivocally determined, and both serine residues conserved in both murine and human Foxp3 were included in further analyses.
(I) In vitro kinase assay with ectopic WT or 7xA mutant HA-Foxp3 immunoprecipitated from HEK293 cells and purified active GST-NLK protein in the presence of
ATP. Samples were analyzed by Phos-tag-SDS-PAGE. IVK, in vitro kinase assay.activity in TCR-mediated Foxp3 phosphorylation, we pretreated
cells with TAK inhibitor (TAKi) to inhibit the activity of TAK1 and
downstream kinases. As shown in lanes 8–14 in Figure 1G, this
inhibition resulted in a marked decrease of all TCR-induced
phosphorylation, suggesting that TCR activation may mediate
the phosphorylation of Foxp3 through Ca2+-mediated activation
of TAK1.NLK Interacts with and Phosphorylates Foxp3
TAK1 is a member of the MAPK family, in which kinases function
as groups of three sequentially acting enzymes that ultimately
phosphorylate an effector protein, generally a transcription fac-
tor (Figure 2A). TAK1 is anMAPKKK that has been demonstrated
to induce the activity of several MAPK family members, including
JNK, p38, and NLK (Ishitani et al., 1999; Shim et al., 2005; WangCell Reports 26, 3600–3612, March 26, 2019 3603
et al., 1997). To identify a putative TAK1-dependent kinase
responsible for Foxp3 phosphorylation, we co-expressed
Foxp3 and several MAPKs that were previously described to
function downstream of TAK1, and cell lysates were analyzed
by Phos-tag SDS-PAGE. Whereas co-expression of p38, JNK,
or ERK did not induce phosphorylation, Foxp3 specifically and
robustly shifted upon the expression of NLK (Figure 2B). This
decreased mobility observed by co-expression with NLK was
due to phosphorylation since lphosphatase (lPPase) treatment
prevented this shift (Figure 2C).
To determine whether Foxp3 can be a direct substrate of NLK,
we first investigated the possible interaction between the two
proteins by co-immunoprecipitation. A clear interaction was
observed when both proteins were ectopically expressed (Fig-
ure 2D). Using the samemethod, we could not detect an interac-
tion between Foxp3 and TAK1 (data not shown). To confirm that
an interaction between Foxp3 and NLK can also occur when
both proteins are endogenously expressed in primary TREG cells,
we next assessed the localization of NLK and Foxp3 in sorted
TREG cells from Foxp3-GFP mice. Co-localization of both pro-
teins was observed in the nucleus (Figure 2E). To further verify
that endogenously expressed Foxp3 and NLK can associate in
TREG cells, we performed a proximity ligation assay (PLA),
enabling the detection of localized protein-protein interactions
in cells, as we have previously described (van Loosdregt et al.,
2013a, 2013b). As a control, CD4+GFP cells that do not express
Foxp3 were used. The association of Foxp3 and NLK, appearing
as localized dots, was observed and appeared specifically in the
nucleus (Figure 2F). The association of NLK and Foxp3 under
these experimental conditions could be because either they
can interact independently of TCR engagement or isolated
CD4+ T cells may already be activated.
To address whether Foxp3 is a direct substrate of NLK, we
subsequently performed an in vitro kinase assay using HA-
Foxp3 immunoprecipitated fromHEK293 cells and subsequently
incubated with purified GST-NLK (Figure 2G). In the presence of
ATP, GST-NLK induced the phosphorylation of Foxp3, indicating
that Foxp3 can indeed be a direct substrate of NLK. The addition
of ATP alone was not sufficient to induce the phosphorylation of
Foxp3, eliminating the possibility that additional kinases poten-
tially co-precipitating with Foxp3 were able to induce phosphor-
ylation.We next sought to determinewhich amino acids could be
phosphorylated by NLK. Both human and murine Foxp3 were
co-expressed with NLK and immunoprecipitated from cell ly-
sates. Using mass spectrometry (MS), as we have previously
described (van Loosdregt et al., 2013a), we identified seven
distinct residues (S19, S156, S189, S273, S278, S295, and
T341), which were detected in both human and murine Foxp3
and phosphorylated exclusively upon the co-expression of
NLK (Figures 2H and S2A–S2F). Mutation of all seven phosphor-
ylated residues to alanine (Foxp3 7xA) resulted in decreased
phosphorylation as measured by Phos-tag analysis (Figure 2I).
These results demonstrate that NLK interacts with Foxp3 and
can directly phosphorylate Foxp3 on multiple residues.
NLK Can Modulate TREG Cell Function In Vivo
Given the potential of NLK to phosphorylate Foxp3 on multiple
residues, we analyzed the role of NLK in TREG cell-mediated sup-3604 Cell Reports 26, 3600–3612, March 26, 2019pression. NLK knockdown in human iTREG cells was performed
using two distinct lentiviral small hairpin RNAs (shRNAs), by
transducing the cells during in vitro differentiation. This resulted
in an approximately 50% reduction in protein levels. Next, iTREG
cell suppressive function was again addressed by means of an
in vitro suppression assay (Figures S3A and S3B). TREG cell-
mediated suppression was significantly abrogated upon the
knockdown of NLK compared to the scrambled (Scr) control,
supporting the hypothesis that NLK modulates TREG cell
function.
To determine whether NLK activity could also modulate TREG
cell-mediated suppression in vivo, we used a mouse colitis
model. Here, naive CD4+CD25CD62Lhi T cells were co-trans-
ferred with CD4+CD25hi NLK knockdown TREG cells into Rag2
/
mice. In contrast to wild-type (WT) or control knockdown TREG
cells, NLK knockdown TREG cells could not suppress the devel-
opment of disease based on both body weight loss and histolog-
ical analysis of the colon (Figures 3A–3C, S3C, and S3D). Both
interferon g (IFN-g and IL-17 production by CD4+ lamina propria
lymphocytes was increased in mice that received NLK knock-
down TREG cells (Figure 3D). TEFF cell numbers in the spleen,
mesenteric lymph node, and lamina propria were increased in
mice that received shNLK TREG cells in comparison to controls
(Figure 3E). In addition, the numbers of transduced and trans-
ferred Thy1.1 TREG cells were similar in both the control and
NLK knockdown groups, demonstrating that NLK knockdown
did not alter TREG cell survival or homing to lymph nodes (Fig-
ure 3F). The percentage of Foxp3+ cells within the Thy1.1 popu-
lation was decreased in mice that received NLK knockdown
TREG cells, indicating that the loss of NLK activity resulted in
decreased Foxp3 protein expression. These data demonstrate
that NLK activity is required to regulate TREG cell-mediated sup-
pression in vivo.
TREG Cell-Specific NLK Deficiency Results in
Inflammation
To overcome the limitations of using a global NLK knockout
mouse to study the role of NLK in TREG cell function in vivo, we
generated a TREG-specific NLK-deficient mouse by crossing
FoxP3Cre mice onto an NLKf/f background (hereafter referred to
as NLKDTreg). We confirmed that in NLKDTreg mice, Nlk message
was effectively ablated in TREG cells but not in other CD4
+ pop-
ulations (Figures S4A and S4B). By 6 weeks of age, NLKDTreg
mice developed mild splenomegaly (Figure 4A), which is indica-
tive of the development of a spontaneous inflammatory
response. Because many autoimmune disorders have an aging
component, we also characterized the phenotype of older
NLKDTreg mice. Accordingly, we observed that the spleens of
NLKDTreg mice became substantially larger than those of WT
littermate controls when these mice reached 6 months of age
(Figure 4B). To further characterize the phenotype of NLKDTreg
mice, we analyzed the cell populations in the spleens of WT
and NLKDTreg littermates of both 6-week-old and 6-month-old
mice. While the percentages of dendritic cells, macrophages,
B cells, and cytotoxic cells were comparable between both
mouse strains (Figures S4C and S4E), we observed an increase
in the percentage of CD4+ T cells and a change in the proportions
of CD4+ T cell subpopulations (Figures 4C and 4D). Specifically,
Figure 3. NLK Is Required for Optimal TREG Cells’ Suppressive Function In Vivo
Colitis was induced by intravenous co-injection of 13 106 CD4+CD25CD62Lhi T cells and 23 105 CD4+CD25hi TREG cells per Rag2
/mouse. TREG cells were
either untreated or transducedwith control or NLK-targeting lentiviral shRNA.Micewere sacrificed 8weeks post-adoptive transfer, and the level of induced colitis
was assessed.
(A) Body weight was analyzed from 0 to 8 weeks post-transfer.
(B) Representative H&E-stained slides of colon sections.
(C) Histological colitis scores of colon sections.
(D–F) Spleen and lymph node (LN) (mesenteric and lamina propria LNs) cells were isolated.
(D) IFN-g and IL-17 production by CD4+ mesenteric and lamina propria lymphocytes, analyzed by ELISA.
(E) The number of TEFF cells in the spleen and LNs was determined by flow cytometry.
(F) Cell numbers of injected Thy1.1+ TREG cells and Foxp3
+ cells were determined by flow cytometry.we observed a reduction in the percentage and number of naive
CD4+ T cells and a significant increase in the percentage
and number of antigen-experienced CD4+ T cells (Figures 4C,
4D, S4D, and S4F). The differences in T helper cell subpopula-
tion percentages were also pronounced, with age correlating
with spleen sizes (Figures 4A–4D). Finally, we observed thatyoung mice had comparable percentages of TREG cells
(CD25hiFoxP3+); however, this cell population dramatically
decreased with age (Figure 4E). Analysis of the expression of
GFP/yellow fluorescent protein (YFP), a reporter of the transcrip-
tional induction of FoxP3, revealed a similar induction of the
Foxp3 gene (Figure 4F), suggesting that NLK deletion does notCell Reports 26, 3600–3612, March 26, 2019 3605
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Figure 4. TREG Cell-Specific NLK-Deficient
Mice Naturally Develop Inflammatory
Responses
Lymphoid tissues were collected from both
6-week-old and 6-month-old Foxp3Cre NLKf/f
mice (NLKDTreg) and NLKf/f littermate controls for
analysis.
(A and B) Inflammation index, calculated as a
spleen weight/body weight for NLKDTreg mice and
NLKf/f littermate controls of 6 weeks old (A) or
6 months old (B). The image in (A) and (B) is a
representative picture of the spleens to illustrate
size.
(C and D) T helper cell subpopulations of the
spleens from NLKDTreg mice and NLKf/f littermate
controls were analyzed by flow cytometry at
6 weeks old (C) or 6 months old (D). Total CD4+
T cells, naive CD4+ T cells, antigen-experienced
CD4+ T cells, and TREG cells are shown as a per-
centage of live splenocytes.
(E) Representative fluorescence-activated cell
sorting (FACS) plots showing Foxp3 staining in live
CD3+CD4+ T cells from 6-week-old and 6-month-
old NLKDTreg mice and NLKf/f littermate controls.
(F) GFP/YFP expression by TREG cells from
6-month-old NLKDTreg mice and age-matched
Foxp3-GFP mice is shown as a percentage of live
splenocytes.
(G) Foxp3 expression (MFI) in TREG cells from
6 months old NLKDTreg mice and age-matched
Foxp3-GFP mice. Results are representative from
two independent experiments (mean ± SEM) and
results for individual mice are shown as dots.
*p < 0.05, **p < 0.01, when compared with NLKf/f
mice. Non-parametric Mann-Whitney test was
used.affect the survival or proliferation of TREG cells, but rather it com-
promises the stability of the Foxp3 protein, as was also observed
in the adoptive transfer colitis model (Figures 3F and S4B).
NLK Prevents Foxp3 Polyubiquitination and Promotes
TREG Cell-Mediated Suppression
To evaluate whether NLK licenses TREG cell-mediated suppres-
sion in vivo, we tested the ability of WT and NLKDTreg TREG cells3606 Cell Reports 26, 3600–3612, March 26, 2019to suppress the proliferation of naive
T cells induced by transfer into lympho-
penic hosts. In this experiment, we trans-
ferred naive CD45.1/2 T cells alone or
mixed 1:1 with CD45.2+ WT or NLKDTreg
TREG cells into lymphopenic RAG-1
/
CD45.1 hosts, allowing for the identifica-
tion of donor versus host cells at the
end of the experiment. Naive T cells
were labeled with CellTrace Violet tracker
before transfer, and the dilution of the
fluorescence of the probe upon cell divi-
sion was used to quantify proliferation.
As shown in Figure 5A, the transfer of
naive T cells into lymphopenic hosts
induced the division of the CD45.1/2transferred cells. This proliferation was efficiently suppressed
by co-transfer of WT TREG cells; however, the transfer of
NLKDTreg TREG cells did not affect the proliferation of naive
T cells, despite being present in the spleens of the hosts in com-
parable quantities. These results suggest that NLK mediates the
phosphorylation of Foxp3, increasing its stability, and in this
manner, NLK allows for the optimal suppressive capacity of
TREG cells.
Figure 5. Reduced Levels of Foxp3 Protein
from NLK-Deficient TREG Due to Increased
Proteasomal Degradation
(A) FACS-sorted CD45.1/2 naive CD4+T cells
(CD4+CD25CD45RBhi) were intravenously (i.v.)
injected (1 3 105) alone (Non-Treg [NT]) or mixed
1:1 with CD45.2 NLKf/f or NLKDTreg TREG cells
(CD4+ YFP+ CD25hi) into CD45.1 Rag1/ re-
cipients. Before transfer, naive T cells were labeled
with CellTrace Violet. After 6 days of transfer,
spleens were harvested, and single cell suspen-
sions were prepared and stained for CD4, CD45.1,
and CD45.2. The dilution of the CellTrace Violet
probe was analyzed by FACS in the naive CD4+
population identified as CD4+ CD45.1+ and
CD45.2+. Results are representative of two inde-
pendent experiments (means ± SEMs), and the
results for individual mice are shown as dots
(except in A). There were three biological replicates
per treatment. *p < 0.05, **p < 0.01, *p < 0.001,
when comparedwith NLKf/f mice, unless otherwise
indicated. Non-parametric Mann-Whitney test was
used.
(B) Reduced phosphorylation of Foxp3 in NLKDTreg
TREG cells.
(C) WT and NLKDTreg TREG cells were FACS
sorted from the spleens of Foxp3-reporter mice
(Foxp3YFP and Foxp3YFP/Cre NLKf/f) by gating in
CD4+ GFP/YFP+ and CD25hi cells. TREG cells were
cultured in the presence of 150 mg/mL cyclohexi-
mide (CHX), as indicated. Foxp3 expression was
determined by flow cytometry.
(D) Analysis of Foxp3 levels in transfected HEK293
cells treated with CHX in the presence or absence
of NLK expression.
(E) All seven phosphorylation sites identified by
mass spectrometry were mutated to the aspartate
phosphomimetic, and samples were analyzed
similarly to (D).
(F) Cells were transfected with His-tagged ubiq-
uitin and Myc-tagged Foxp3 in the presence or
absence of NLK or STUB1. A ubiquitin pull-down
assay was performed as described in Method
Details. Foxp3-specific ubiquitination was deter-
mined by western blot analysis of Myc-Foxp3.
(G) Lysates of Myc-Foxp3 and HA-STUB1 trans-
fected cells with or without Myc-NLK were immu-
noprecipitated with anti-Myc coupled beads.
Immunoblots were analyzed with anti-Myc, anti-
HA, and anti-FLAG.To evaluate whether NLK-mediated phosphorylation of Foxp3
can indeed regulate Foxp3 stability, we assessed the phosphor-
ylation of Foxp3 in WT compared with NLKDTreg TREG cells. As
shown in Figure 5B, NLKDTreg TREG cells showed reduced phos-
phorylation of Foxp3 at steady-state conditions. To determine
the impact of the NLK-mediated phosphorylation of Foxp3, we
measured Foxp3 expression in WT and NLKDTreg TREG cells
from young mice after CD3/CD28 stimulation in the presence
of the protein translation inhibitor cycloheximide (CHX). By inhib-
iting protein translation, the production of new Foxp3 protein is
prevented, and in this way, the stability of Foxp3 protein expres-
sion can be qualitatively evaluated. CD3/CD28 stimulation com-
bined with the inhibition of translation led to a rapid decrease inFoxp3 protein in both WT and NLKDTreg TREG cells (Figure 5C).
However, the loss of Foxp3 expression in NLKDTreg TREG cells
occurred significantly faster, even though Foxp3 levels were
comparable in both WT and NLKDTreg TREG cells at the start of
the experiment (Figure 5C). These observations suggest that
NLK-mediated phosphorylation of Foxp3 enhances its stability.
To determine whether NLK-mediated phosphorylation could
result in increased Foxp3 protein levels, we assessed Foxp3
expression in HEK293T cells that were co-transfected with or
without NLK in the presence of CHX. As observed in primary
TREG cells, the addition of CHX resulted in the loss of Foxp3
expression, while the ectopic expression of NLK noticeably
increased Foxp3 protein amounts (Figure 5D). These data furtherCell Reports 26, 3600–3612, March 26, 2019 3607
Figure 6. NLK-Deficient TREG Cell Animals Develop More Severe
Experimental Autoimmune Encephalmyelitis (EAE)
(A) Both NLKfl/fl and NLKDTreg mice were injected subcutaneously (s.c.) with
100 mg MOG35–55 in complete Freund’s adjuvant (CFA) and 250 ng pertussis
toxin (PT) intraperitoneally (i.p.). Disease severity was scored every 2 days.
Scores for each group over time are presented as means ± SEMs (p < 0.05,
n = 6–8 per group).
(B) On day 30, CNS (brain and spinal cord)-infiltrating T cells were recovered
and stained for CD4 and Foxp3. Secretion of IL-17 and IFN-g within the CD4+
population was determined after stimulation with PMA and ionomycin. The
mean percentages of IL-17+, IFN-g+, and Foxp3+ cells among CNS-infiltrating
CD4+ cells on day 30 were determined.
Results were obtained from three individual experiments and presented as
means ± SEMs. *p < 0.05.support amodel whereby NLK-mediated Foxp3 phosphorylation
prevents Foxp3 degradation. Since we had identified several po-
tential NLK phosphorylation sites on Foxp3 (Figures 2H and 2I),
we also evaluated the stability of a phosphomimetic mutant
(Foxp3 7xD). Here, the Foxp3 7xD mutant demonstrated
increased protein expression both in the presence and absence
of CHX, suggesting increased protein stability (Figure 5E). We
have previously demonstrated that Foxp3 is subject to regulation
by K48-linked ubiquitination by the STUB1 E3-ligase and deubi-
quitination by USP7-regulating levels of Foxp3 protein (Chen
et al., 2013; van Loosdregt et al., 2013a). To evaluate whether
NLK-mediated Foxp3 phosphorylation could modulate poly-
ubiquitination, HEK293T cells transfected with both His-tagged
ubiquitin and hemagglutinin (HA)-tagged Foxp3 were lysed,
and ubiquitinated proteins were isolated with nickel-nitrilotriace-
tic acid (Ni-NTA) beads, as previously described (van Loosdregt
et al., 2013a). Foxp3-specific polyubiquitination was determined
by immunoblot analysis with anti-HA. A clear polyubiquitination
pattern was observed with WT Foxp3 (Figure 5F, lane 2), and3608 Cell Reports 26, 3600–3612, March 26, 2019this was greatly reduced upon co-transfection of NLK (Figure 5F,
lane 3), indicating that Foxp3 polyubiquitination can be inhibited
by NLK. Co-transfection of the STUB1 E3-ligase resulted in a
robust increase in Foxp3 polyubiquitination, as we have previ-
ously reported (Figure 5F, lane 4) (Chen et al., 2013); however,
co-transfection of NLK again resulted in a large reduction in
Ubi-Foxp3 (Figure 5F, lane 5). Finally, to identify a mechanism
by which NLK could interfere in STUB1-mediated Foxp3 poly-
ubiquitination, we evaluated the interaction between STUB1
and Foxp3 in the presence and absence of NLK. Co-transfection
of Foxp3 and STUB1 followed by immunoprecipitation of STUB1
revealed a clear interaction between these two proteins (Fig-
ure 5G, lane 4). However, the expression of NLK resulted in
greatly decreased interactions between Foxp3 and STUB1 (Fig-
ure 5G, lane 7), providing a mechanistic explanation of reduced
Foxp3 polyubiquitination and increased Foxp3 protein levels un-
der these conditions. No changes in association between Foxp3
and USP7 were observed (Figure S5A).
These results demonstrate that NLK can prevent Foxp3 poly-
ubiquitination, most likely by preventing the association between
Foxp3 and STUB1, providing a mechanism for the increased
Foxp3 protein turnover in NLK-deficient TREG cells.
NLK-Deficient TREG Cell Animals Develop More Severe
Experimental Autoimmune Encephalomyelitis
To test the physiological relevance of our previous observations,
we induced experimental autoimmune encephalomyelitis
(EAE) in mice with NLK deficiency in Foxp3+ TREG cells. This
MOG35–55 mousemodel of multiple sclerosis is a CD4
+ T helper 1
(TH1)-mediated autoimmune disease in which autoreactive
T cells specific for myelin components enter the CNS, initiating
a cascade of inflammation and demyelination. CD4+CD25hi
TREG cells have been shown to suppress antigen-specific autor-
eactive immune responses and CNS inflammation during active
EAE (Kohm et al., 2002; McGeachy et al., 2005). As also
observed under homeostatic conditions (Figure 4), NLKDTreg an-
imals displayed more advanced, severe disease than WT litter-
mates (Figure 6A). While total cell counts and frequencies of
CD4+ infiltrated T cells in CNS were comparable (data not
shown), the frequencies of Foxp3+ cells among CD4+ T cells
were increased in the brains of NLKDTreg mice, presumably in a
compensatory mechanism, although this was not significant. In
keeping with a more robust immune response, NLKDTreg mice
harbored higher proportions of IL-17 and IFN-g-producing
CD4+ cells, with an emphasis on TH1 immune response in their
spinal cords during the recovery phase than did NLKfl/fl litter-
mates (p < 0.05) (Figures 6B and S6). These findings support a
role for NLK expression in sustaining TREG cell functionality and
regulating autoimmune responses in vivo.
DISCUSSION
Tight control of TREG cell suppressive function is required to
establish a balanced immune response, given the cells’ central
role in immune regulation and peripheral tolerance. Human
Foxp3+CD4+CD25+ TREG cells may not be stable, encountering
the loss of Foxp3 expression or conversion into effector T
(TEFF)-like cells (Koenen et al., 2008; Valmori et al., 2010; Voo
et al., 2009). Furthermore, it has been observed under inflamma-
tory conditions that the suppressive capacity of TREG cells can be
diminished (e.g., through exposure to pro-inflammatory cyto-
kines such as IL-6) (Pasare and Medzhitov, 2003) or enhanced
(e.g., by exposure to the epidermal growth factor (EGF)-like
growth factor amphiregulin) (Zaiss et al., 2013). Evidence that
Foxp3 expression and activity are subjected to post-transla-
tional modulation to establish the regulation of TREG cell activity
is emerging (Lu et al., 2017; van Loosdregt and Coffer, 2014).
Thus, a critical area of TREG cell research remains to understand
the mechanisms by which extracellular signals regulate the
expression and function of Foxp3.
Here, using a combination of in vitro and in vivo approaches,
we have identified and characterized a novel NLK-mediated
phosphorylation-ubiquitination ‘‘switch’’ that regulates the
Foxp3 protein levels, and we demonstrate that NLK is critical
for the maintenance of immune tolerance in vivo. These data
may have implications for both natural and peripheral TREG cell
stability or plasticity and differentiation, as well as ensure that
activation-induced Foxp3 expression in human TEFF cells re-
mains a transient phenomenon and does not lead to the inappro-
priate generation of peripheral TREG cell populations. Our initial
observations identified TAK1 as a regulator of TCR-induced
Foxp3 phosphorylation (Figures 1G and 1H). TAK1 functions at
the crossroads ofmultiple signal transduction pathways and reg-
ulates the activity of various transcription factors that are impor-
tant in immune regulation, including activator protein 1 (AP-1)
and NF-kB, and TAK1 activation specifically triggered by TCR
signaling has been shown to induce both NF-kB and MAPK ac-
tivity (Shim et al., 2005; Sun et al., 2004; Wan et al., 2006; Wang
et al., 1997). In our studies, both pharmacological inhibition and
ectopic expression of TAK1 downstream effectors revealed that
the regulation of Foxp3 phosphorylation was specifically medi-
ated by NLK. Combined with the finding that the manipulation
of Foxp3 expression, and thus transcriptional activity, is suffi-
cient to modulate TREG cell function (Williams and Rudensky,
2007), these findings indicate that TAK1 and NLK regulated
TREG cell suppressive capacity at least in part through the modi-
fication of Foxp3 protein.
Stimulation of TCR activation is not only a crucial factor for the
generation of both thymic and peripheral TREG cells but is further-
more important for TREG cell function (Apostolou and von
Boehmer, 2004; Jordan et al., 2001; Kretschmer et al., 2005).
The activation of mature TREG cells by TCR ligation induces
expansion in vivo, rendering a TREG cell population with
enhanced suppressive capacity (Klein et al., 2003; Kretschmer
et al., 2005; Walker et al., 2003). TCR ligation is also a require-
ment for extrathymic differentiation of TREG cells and is depen-
dent on TCR ligand density and affinity (Gottschalk et al.,
2010). It has been suggested that the cumulative level of TCR
stimulation determines the initial induction of Foxp3 in the pe-
riphery, but that TCR ligand density and potency both are impor-
tant in regulating the persistence of Foxp3+ populations. It could
be that NLK activation acts as a sensor of the level of TCR acti-
vation by antigen, and in this way can allow the rapid and tran-
sient regulation of Foxp3 protein expression levels. A similar
role for PKB/AKT and mTOR have been proposed for the regula-
tion of Foxp3 transcription (Haxhinasto et al., 2008; Sauer et al.,2008), and these pathways may complement each other in
providing robust and transient regulation of TREG cell function-
ality. While the activation of TCR signaling was believed to
predominantly regulate Foxp3 gene transcription (Josefowicz
et al., 2012; Mantel et al., 2006; Walker et al., 2003), we provide
novel evidence for the modulation of Foxp3 transcriptional activ-
ity by TAK1-NLK-mediated phosphorylation. Mediation of both
transcriptional and post-translational regulation of Foxp3 activity
by TCR signaling would enable robust temporal control of Foxp3
function. Therefore, manipulation of the TAK1-NLK axis could
provide a mechanism to transiently modulate TREG cell function
and, ultimately, the intensity and duration of immune responses.
NLK function has been implicated in a variety of develop-
mental processes, including wing and eye development in
Drosophila melanogaster, endoderm development in Caeno-
rhabditis elegans, mesoderm as well as anterior head formation
in Xenopus laevis, and hematopoiesis in the mouse (Choi and
Benzer, 1994; Kortenjann et al., 2001; Ohkawara et al., 2004; Ro-
cheleau et al., 1999; Sato et al., 2006; Zeng et al., 2007). These
findings point toward a common role for NLK in embryonic devel-
opment and cell fate determination. Our current observations
demonstrate that specific loss of NLK expression in TREG cells
results in an age-dependent reduction in TREG cell numbers,
eventually resulting in the development of inflammation. There
does not appear to be a problem with TREG cell development
per se, since younger animals have normal numbers of
CD4+CD25hiFoxp3+ lymphocytes (Figure 4). This suggests that
at least thymic-derived TREG cell numbers may not be perturbed
by the lack of NLK. However, within 6 months, there is an almost
total disappearance of CD4+CD25hiFoxp3+ cells through an as
yet unidentified mechanism, which parallels the loss of Foxp3
protein. The observation of a gradual loss of Foxp3 expression
and TREG cell numbers suggests that NLK activity is required
constitutively after thymic selection to maintain homeostatic
TREG cells numbers. Mice deficient in Foxp3 develop fatal auto-
immune disease (Fontenot et al., 2003; Hori et al., 2003), while
the continuous expression of Foxp3 throughout life prevents
autoimmunity (Kim et al., 2007). In accordance with these find-
ings, we found that in contrast to WT mice, NLKDTreg animals
developed signs of colon inflammation at 6 months (data not
shown).
Phosphorylation of Foxp3 has been described before,
although the physiological relevance of these post-translational
modifications remains unresolved. The highly related Pim1 and
Pim2 kinases, for instance, have been shown to phosphorylate
Foxp3 and negatively regulate transcriptional output, although
through distinct mechanisms. Pim1 kinase phosphorylates hu-
man, but not murine, Foxp3 at serine-422 and results in reduced
DNA binding and activation (Li et al., 2014), while Pim2 kinase
was found to phosphorylate the Foxp3 N terminus (Deng et al.,
2015). Accordingly, global Pim2 gene deficiency resulted in
increased TREG cell lineage stability, and Pim2 knockout animals
have increased resistance to dextran sulfate sodium (DSS)-
induced colitis. These experiments did not use conditional
Pim2 knockout mice, which makes the TREG cell-specific impor-
tance of these observations difficult to evaluate. Similarly, the
cyclin-dependent kinase CDK2 was reported to directly phos-
phorylate the N terminus of Foxp3, resulting in increasing proteinCell Reports 26, 3600–3612, March 26, 2019 3609
turnover (Morawski et al., 2013). However, it remains unclear as
to when or where such CDK2-mediated regulation occurs under
physiological conditions. Lastly, amphiregulin (AREG) signaling
through the EGF receptor has been shown to inhibit GSK-
3b-mediated phosphorylation of Foxp3 in vitro (Wang et al.,
2016). We have previously demonstrated that AREG enhances
TREG cell function, and GSK-3b may therefore play a role in this
process. While these observations support the idea that Foxp3
phosphorylation may play a role in regulating TREG cell function,
none of these studies has explored the relevance of their findings
in relevant, conditional knockout in vivo models, making the
extrapolation of these data with regard to the regulation of im-
mune tolerance difficult.
Our data reveal a critical role for NLK-mediated phosphoryla-
tion of Foxp3. NLK was found to interact with and have the po-
tential to phosphorylate Foxp3 on multiple residues. However,
Foxp3 is not the only target of NLK, and while there are few
studies that have evaluated NLK substrates in detail, the re-
ported mechanisms by which NLK functions are quite diverse,
ranging from regulation of protein stability to DNA binding and
recruitment of co-factors, often leading to decreased transcrip-
tional activity (Kurahashi et al., 2005; Sato et al., 2006; Zhang
et al., 2014, 2015). NLK has been both positively and negatively
implicated in the stabilization of the protein expression of the
transcription factors c-Myb, p53, and activating transcription
factor 5 (ATF5) through a variety of mechanisms. Fbxw7, for
example, targets c-Myb for ubiquitin-mediated proteosomal
degradation in an NLK-dependent manner (Kanei-Ishii et al.,
2008), while the association of NLK with ATF5 or p53, for
instance, prevented their proteasomal degradation (Zhang
et al., 2014, 2015). Furthermore, NLK was found to promote
the acetylation of p53, and Foxp3 expression and activity have
also been shown to be regulated through themodulation of acet-
ylation, allowing for rapid and transient control of Foxp3 protein
levels (Lu et al., 2017; van Loosdregt and Coffer, 2014). It would
be interesting to determine in future experiments whether NLK
may also stabilize Foxp3 expression by promoting increased
acetylation.
Our data show that NLK positively sustains TREG suppressive
function, likely through phosphorylation-dependent deubiquiti-
nation of Foxp3. Since the balance between tolerance and auto-
immunity can be regulated by Foxp3 stability, our observations
concerning the NLK-mediated control of Foxp3 proteasomal
degradation can have therapeutic implications. The develop-
ment of a targeted NLK inhibitor, for example, may provide a
way of eliminating TREG cells from the tumor microenvironment
with potential beneficial treatment outcome effects.STAR+METHODS
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Anti-CD3/CD28 Dynabeads ThermoFisher 11452D
TGF-b R&D systems 240-B-010
RNasin inhibitor Promega N2111
dNTPs Promega 28-4065-60
(Continued on next page)
Cell Reports 26, 3600–3612.e1–e6, March 26, 2019 e1
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Oligo dT15 Promega C1101
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cultured Cells
Human embryonic kidney (HEK) 293 cells were maintained in Dulbecco’s modified Eagle’s medium containing Glutamax (GIBCO),
supplemented with 8% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, and 100 mg/ml streptomycin (GIBCO).
Genetic mouse models
Foxp3-GFP mice were kept in the animal facility of the Utrecht University and experiments were approved by the Animal Experiment
Committee of the Faculty of Veterinary Medicine (Utrecht University). C57BL/6J mice (WT, Nlkfl/fl, Foxp3-cre/YFP x Nlkfl/fl) were bred
and maintained at the University of Edinburgh in specific-pathogen free conditions. Sex-matched mice were 6-8-weeks or 6 months
old at the start of the experiment, and all mice were housed in individually ventilated cages. Experiments were performed in accor-
dance with the United Kingdom Animals (Scientific Procedures) Act of 1986. All researchers were accredited by the UK government
Home Office. Dispensation to carry out animal research at The University of Edinburgh was approved by the University of Edinburgh
Animal Welfare and Ethical Review Body and granted by the UK government Home Office.
METHOD DETAILS
Antibodies and reagents
The following antibodies were used: rat anti-Foxp3 clone PCH101 andmouse anti-Foxp3 clone eBio7979 (eBioscience), mouse anti-
Flag (Sigma-Aldrich), mouse anti-hemaglutinin (HA) clone 12CAS, rabbit anti-NLK (H-100) and goat anti-Actin (I-19) (Santa Cruz
Biotechnology), and anti-HSP90 was purchased from Professor Ineke Braakman (UMC Utrecht, Utrecht, the Netherlands).
The following reagents were used: Phos-tagTM Acrylamide (WAKO Chemicals GmbH), Okadaic acid, SB203580, SP600125,
U-0126 and Rapamycin (Enzo Lifesciences), PKB inhibitor VIII (Calbiochem), 5Z-7-Oxozeaenol and BIO (Tocris Bioscience, Bristol,
United Kingdom, lPPAse (New England BioLabs) and recombinant GST-NLK active protein (Sigma-Aldrich).
Construct design
pMT2 HA-Foxp3(van Loosdregt et al., 2013b), HA-JNK, HA-P38, HA-ERK (de Groot et al., 1997), and His-Ubi, myc-USP7, myc-
Foxp3, pLP/VSVG and psPAX2(van Loosdregt et al., 2013a) were described previously. pMT2-Flag NLK was kindly provided
by B. Burgering (Szypowska et al., 2011). MISSION pLK0.1 puro NLK human shRNA TRCN0000002071 and TRCN0000195090
were purchased from Sigma-Aldrich. pRFP-C-RS Nlk mouse shRNA was purchased from OriGene Technologies. Stub1 was pur-
chased from Harvard Medical school, pUC57 Foxp3 7xA and 7xD were synthesized by Genscript Biotech, and cloned into pMT2
containing an N-terminal HA-tag generating pMT2-HA-Stub1, pMT2-HA-Foxp3 7xA and 7xD respectively.
Immunoprecipitation
For Co-immunoprecipitation, HEK293 cells were transfected with PEI in 60 mm tissue culture dishes, and 48 hours post transfection
cells were lysed in NP-40 lysis buffer (50 mM Tris-HCl pH 7.5, 0.5% Nonidet p40 (US Biologicals), 150 mM NaCl, 10 mM EDTA, sup-
plemented with 1% HALT protease inhibitor cocktail (Thermo Scientific). Cell lysates were cleared by high speed centrifugation.
Immunoprecipitation was performed utilizing anti-FLAG M2 affinity gel or anti-HA conjugated beads (Sigma-Aldrich). Precipitates
were washed 3 times in lysis buffer, boiled, and analyzed by Western Blotting.
Generation of induced regulatory T cells
CD4+CD25- cells were isolated from human umbilical cord blood by magnetic-activated cell sorting and cultured in RPMI 1640
(GIBCO) supplemented 10% FCS, 100 Units/ml penicillin, 100 mg/ml streptomycin, and 5 3 105 M 2-mercaptoethanol. Foxp3
expression and TREG cell differentiation was induced by culturing the cells for 5 days in combination with CD3/CD28 Dynabeads
(GIBCO), 300 IU IL-2, and 10 ng/ml TGFb.
Western blotting: conventional and Phos-tag
For conventional western blotting, samples were lysed in NP-40 Lysis buffer, and protein concentrations were determined using a
Lowry protein assay. Proteins were separated by SDS-PAGE, electrophoretically transferred to polyvinylidene difluoride (PVDF)
membrane (Millipore). Membranes were hybridized with antibodies as indicated. Immunocomplexes were detected using ECL
(AmershamPharmacia Inc.). For Phos-tag SDS-PAGE, 50 mMPhos-tagTM Acrylamide was used and analysis was performed accord-
ing to the manufacturer’s protocol.Cell Reports 26, 3600–3612.e1–e6, March 26, 2019 e3
Quantitative RT-PCR
Total RNA was extracted using the RNAeasy kit (QIAGEN) and treated with RNase free DNase (QIAGEN) to eliminate genomic DNA
contamination. cDNA synthesis was performed with an iScript cDNA Synthesis Kit (Bio-Rad). cDNA samples were amplified with
SYBR Green Supermix (Bio-Rad) in a MyiQ Single-Color Real-Time PCR Detection System (Bio-Rad) according to the manufac-
turer’s protocol. For quantification the comparative Ct method was used. Relative quantity was defined as 2-DDCt and b2-microglo-
bulin was used as a reference gene.
In vitro suppression assays
HumanCD4+CD25hiCD127lo TREG cells were sorted from human PBMCs and cocultured with PBMCs labeled with 2 mM CFSE (at
ratios of 1:10, 1:5, 1:2, and 1:1) in anti-CD3 (clone OKT3)-coated 96-well plates. Cells were cultured for 4 days in RPMI medium sup-
plemented with 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, and 53 105 M2-bmercaptoethanol. Proliferation of CD4+
cells was determined bymeasuring CFSE dilution with a FACSCANTOII Analyzer (BD Biosciences). Suppression was determined by
a comparison of the percentage of proliferating cells with or without TREG cells.
Confocal imaging
Cells were adhered to poly-L-Lysine (Sigma-Aldrich) coated glass slides (Thermo Scientific), and fixed and permeabilized using the
Foxp3 staining kit (eBioscience). Samples were washed in Permeabilization buffer (PB) (eBioscience) and blocked in Block buffer (PB
supplemented with 10% normal donkey serum (Jackson Immunoresearch Laboratories)). Subsequently, samples were incubated
overnight at 4C with block buffer containing antibodies recognizing NLK and Foxp3 as indicated. Subsequently, cells were used
for localization studies, or Proximity Ligation Assay.
Localization studies
Samples were washed 3x in PB and incubated at 22C for 1 hour with secondary antibodies anti-mouse-alexa488, and anti-rabbit-
alexa546 as indicated. Samples were washed 3 times in PB and mounted in mowiol (3% 1,4-diazabiclo- (2,2,2)-octan followed by a
glass cover. Samples were analyzed with a 63X objective on a Zeiss LSM 710 microscope (Carl Zeiss).
Proximity Ligation Assay (PLA):
Cells were washed 3 times in PB and incubated in mouse PLUS and rabbit MINUS probes (Sigma Aldrich) according to the manu-
facturer’s protocol. Cells were washed in PB before detection using the in situ PLA detection kit (Sigma-Aldrich) as previously
described (van Loosdregt et al., 2011). Samples were analyzed with a 63x objective on a Zeiss LSM 710 microscope (Carl Zeiss).
Mass spectrometry and mutational analysis
Human or mouse HA-Foxp3 was ectopically expressed in HEK293 cells with or without ectopic flag-NLK. After immuno-precipitation
ofHA-Foxp3, proteins were on-bead digested in 2M Urea, 50 mM Ammonium BiCarbonate (ABC) and finally desalted with home-
made C-18 stagetips (3M, St Paul, MN). Peptides were separated on-a 30 cm column (75-mm ID fused silica capillary with emitter
tip, New Objective, Woburn, MA) packed with 3-mm aquapur gold C-18 material (Dr Maisch, Ammerbuch-Entringen, Germany) using
a 3-hour gradient (0%–80% Acetonitrile), and delivered by an easy nanoflow high-performance liquid chromatography (nHPLC)
(Thermo Scientific). Peptides were electrosprayed directly into a LTQ-Verlos-Orbitrap (Thermo Scientific) and analyzed in data-
dependent mode with the resolution of the full scan set at 30,000, after which the top 10 peaks were selected for Higher energy Colli-
sion-induced Dissociation (HCD) fragmentation (set at a normalized energy of 40%) and detection in the Orbitrap with a target setting
of 5000 ions at a resolution of 7500. Raw files were analyzed with Maxquant software, version 1.6.1.0. For identification, the mouse
Uniprot database was searched with oxidation of methionine and STY phosphorylation set as variable modifications, and carbami-
domethylation of cysteine set as fixed modification, while peptide and protein false discovery rates were set to 1%.
ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD011164.
For mutational analysis, Foxp3 phosphorylation was assessed in two independent experiments, each comparing human and
mouse Foxp3 with or without overexpression of NLK. Phosphorylated serine and threonine residues that were both identified only
upon co-expression of NLK and conserved between human and murine Foxp3 were selected. For the 7 identified conserved
NLK-dependent residues, expression plasmids encoding phospho-dead (Foxp3 7xA) or phosho-mimetic (Foxp3 7xD) variants
were generated for biochemical and functional analysis (see above).
Colitis induction and histological assessment
Naive CD4+CD25CD62Lhi T cells were isolated from BALB/c and intravenously injected into BALB/c Rag2/ immunodeficient
recipients (1x10e6 per mouse). CD4+CD25highTREG cells TREG cells (2x10e5) isolated from Thy1.1 BALB/c were transduced with or
shCTR- or shNLK HEK293-derived lentivirus as we have previously described (Chen et al., 2013; van Loosdregt et al., 2013a) and
intravenously coinjected where indicated. Mice weremonitored weekly for wasting disease. After 8 weeks, mice were sacrificed. Co-
lons were removed from mice 8 weeks after T cells reconstitution and fixed in 10% formalin. Five-micrometer paraffin-embedded
sections were cut and stainedwith hematoxylin and eosin (H&E). Pathology of colon tissuewas scored in a blinded fashion, on a scale
of 0-5 where a grade of 0 was given when there were no changes observed. Changes associated with other grades were as follows:
grade 1, minimal scattered mucosal inflammatory cell infiltrates, with or without minimal epithelial hyperplasia; grade 2, mild scat-
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moderate epithelial hyperplasia and mild to moderate mucin depletion from goblet cells; grade 3, moderate inflammatory cell
infiltrates that were sometimes transmural, with moderate to severe epithelial hyperplasia and mucin depletion; grade 4, marked in-
flammatory cell infiltrates that were often transmural and associated with crypt abscesses and occasional ulceration, with marked
epithelial hyperplasia, mucin depletion; and grade 5, marked transmural inflammation with severe ulceration and loss of intestinal
glands.
Isolation of lamina propria leukocytes (LPL)
Mice were euthanized and the colons excised and placed in ice-cold PBS. After extensive washing of the colonic lumen with PBS,
colons wereminced into 0.3-0.5cmpieces, and repeatedly incubated in Ca- andMg-free HBSS containing 10%FCS and 5mMEDTA
to release intestinal epithelial cells. The remaining tissue was further incubated with a digestion cocktail [Liberase and DNaseI
(Roche)] at 37C for 1h, and the LPL were then layered on discontinuous Percoll gradient (Amersham Biosciences). After centrifuga-
tion for 30 min at 2000 rpm at room temperature, the LPL population was recovered at the 40%/75% interphase, washed twice in
HBSS/BSA, and counted by trypan blue staining.
Splenocyte preparation and flow cytometry analysis
Single cell suspensions of spleens were obtained by forcing the tissue through a 70 mmcell strainer. Subsequently, cells were treated
with red blood cell lysis buffer (Sigma-Aldrich) and counted using an automated cellometer T4 (Peqlab).
Cells were incubated with Fc block (CD16/CD32 and 10%mouse serum) and stained with a combination of the following commer-
cial monoclonal fluorescently conjugated antibodies: CD4, CD62L, CD44, CD45Rb, CD25, CD45.1, CD45.2, CD8, CD19, SiglecF,
Ly6G, CD3, CD11c, CD11b, F4/80, I-A/I-E (MHCII), and NK-1.1. For detection of Foxp3, cells were stained for surface markers
then fixed and permeabilized using Foxp3 staining buffer set (eBioscience). Cells were then stained with anti-Foxp3 for 30 min at
room temperature. Live/Dead (Life Technologies) was used to exclude dead cells from analysis. Samples were analyzed by flow
cytometry using Becton Dickinson FACS LSR II and FlowJo software. T cells were defined by the expression of CD45, and CD3.
Cytotoxic T cells identified by the expression of CD8 and TH cells by the expression of CD4. Naive and antigen experienced TH
cell subpopulations were further characterized by their expression of CD62L, CD44 and CD45RB (naive: CD62L+ CD44lo CD45RBhi
and antigen experienced: CD62L- CD44hi CD45RBlo). TREG cells were defined as CD25
hi and Foxp3 or YFP positive. In some exper-
iments, TREG cells were sorted using the same gating strategy.
RNA extraction and quantitative real-time PCR
TREG cells were homogenized in TRIzol and RNA was isolated following manufacturer’s instructions. Reverse transcription was per-
formed using 1 mg of total RNA using 200 U of M-MLV reverse transcriptase, 10 mM dNTPs, and 0.5 mg Oligo dT15 and RNasin
inhibitor (Promega). Expression of genes of interest was measured by real-time PCRwith the Lightcycler 480 II system (Roche) using
Taqman Master kit and specific primers for Nlk, as previously described. PCR amplification was analyzed using 2nd derivative
maximum algorithm (LightCycler 480 Sw 1.5, Roche) and Nlk expression was normalized to the housekeeping gene Rn18s.
Foxp3 stability assay
TREG cells were cultured in IMDMmedium supplemented with 10% FCS, 1% l-glutamine, 1% penicillin/streptomycin and 5x10e-5 M
b2-mercaptoethanol at 37C in a humidified atmosphere at 5% CO2. Sorted TREG cells were treated with 150 mg/ml cycloheximide
(CHX) (Sigma) for 0, 0.5, 2 and 4 hr. Next, cells were stained for FoxP3 as described above.
In vivo TREG cell suppression experiments
2.5-5 3 10e5 naive (CD45.1/2+) CD4+ T cells were i.v. injected alone or mixed 1:1 with sorted CD45.2+ NLK-sufficient or NLK-defi-
cient TREG cells into RAG-1
/CD45.1 hosts. Naive T cells were labeled with the CellTrace Violet tracker (Thermofisher) before trans-
fer per manufacturer’s instructions. 6 days after transfer recipient mice were sacrificed and spleens were collected for quantification
of the proliferation of naive T cells.
Lentiviral shRNA knockdown
Virus-containing supernatants were obtained from HEK293T cells transfected using PEI (Polysciences) with pLP/VSV, psPAX2 and
pLKO.1 puro lentiviral shRNA vector (1:2:3 ratio). Murine primary CD4+CD25hi TREG cells were transducedwith shRNACTR or shRNA
NLK lentivirus as we have previously described (Chen et al., 2013; van Loosdregt et al., 2013a).
Human umbilical cord blood-derived CD4+CD25- T cells were isolated and TREG differentiation was induced by culturing the cells in
presence of CD3/CD28 Dynabeads, 300 IU IL-2, and 10 ng/ml TGFb. After O/N culture, cells were transduced by addition virus su-
pernatant (1:1) supplementedwith polybrene (1mg/ml) and IL-2 and TGFb added to restore concentrations (300 IU IL-2, and 10 ng/ml
resp.), followed by centrifugation (1hr at 2000RPM and 30C) and O/N Culture. Next, cells were pellet and transduction procedure
repeated. After O/N culture media was replaced with RPMI + IL-2 and TGFb, supplemented with puromycin (1 mg/ml) and cells
were cultured for 2 days. Next, Dynabeads were removed by magnet separation, cells were washed 3x and cultured in RPMI + pu-
romycin (1mg/ml) and lL-2 + TGFb. After 2 days puromycin resistance was used as an indicator of successful transduction (FACS
sorting).Cell Reports 26, 3600–3612.e1–e6, March 26, 2019 e5
EAE induction and scoring
6 to 8 weeks old, sex-matched NLKfl/fl and NLKDTreg mice littermates were injected subcutaneously in the rear flank with 100 ug
MOG35-55 peptide (2HNMEVGWYRSPFSRVVHLYRNGK-COOH) in complete Freund’s adjuvant (CFA) (Sigma) on day 0, and
250ng pertussis toxin (List Biological) was injected intraperitoneally on day 0 and day 2 post-induction. Mice were monitored and
disease severity was scored every two days. Clinical signs of EAE were assessed with a 0 to 5-point scoring system: 0, normal;
1, flaccid tail or hind-limb weakness; 2, moderate hind-limb paralysis; 3, full hind-limb paralysis; 4, quadriplegia; 5, death. ‘‘In-
between’’ scores (0.5, 1.5, 2.5, 3.5, 4.5) is applied when the clinical picture lies between two defined scores (Taylor and Kitaichi,
2008).
QUANTIFICATION AND STATISTICAL ANALYSIS
If not stated otherwise, data are represented as mean ± SEM p values less than 0.05 were considered statistically significant.e6 Cell Reports 26, 3600–3612.e1–e6, March 26, 2019
